← Back to Search

Other

MBX 2109 (Part A) for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by MBX Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 40 (part a) or day 60 (part b)
Awards & highlights

Summary

This trial tests a new drug called MBX 2109, given as an injection under the skin, in healthy volunteers. The study aims to see how the drug is processed by the body, its effects, and if it is safe.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 40 (part a) or day 60 (part b)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through day 40 (part a) or day 60 (part b) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measures
Secondary study objectives
Measures 1
Measures 2

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: MBX 2109 (Part B)Experimental Treatment1 Intervention
Repeated ascending SC doses
Group II: MBX 2109 (Part A)Experimental Treatment1 Intervention
Single ascending SC doses
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MBX 2109 (Part A)
2021
Completed Phase 1
~80
MBX 2109 (Part B)
2021
Completed Phase 1
~80

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

MBX BiosciencesLead Sponsor
4 Previous Clinical Trials
212 Total Patients Enrolled
Mary Jane Geiger, MD, PhDStudy DirectorMBX Biosciences
~19 spots leftby Oct 2025